Printer Friendly

MACROCHEM LICENSES SEPA TECHNOLOGY TO UPJOHN FOR USE IN MALE IMPOTENCY

 LEXINGTON, Mass., Jan. 25 /PRNewswire/ -- MacroChem Corporation (NASD Bulletin Board: MCHM) announced today it has granted exclusive worldwide license rights to its SEPA(TM) drug delivery enhancer technology to The Upjohn Company (NYSE: UPJ) for use in treating male impotency, also known as erectile dysfunction. This disorder affects some 10-20 million men in the United States.
 SEPAs assist in the delivery of drugs from the skin's surface into the bloodstream. Upjohn is currently testing the SEPAs in a formulation with the aim of developing a topically applied product for erectile tates, Canada, Europe and pending in Japan. The company has also filed an additional SEPA patent application in the United States and expects to file it in Canada, Europe and Japan.
 MacroChem is also developing an iontophoretic dermal delivery system, which uses mild electrical currents for transdermal drug delivery, and is part of the agreement with Upjohn. This drug delivery system will also be studied for use in treating erectile dysfunction. Patent applications on this technology have been filed in the United States, Canada, Europe and Japan.
 Under the terms of the license agreement, Upjohn will pay MacroChem a license fee which will be followed by milestone payments. Upjohn will be responsible for product development. Once marketed, Upjohn will pay MacroChem royalties on its product sales.
 "All of us at MacroChem are extremely pleased to have this second license arrangement in place with Upjohn and we look forward to mutual benefits from both," stated MacroChem President Alvin J. Karloff.
 Upjohn is currently testing the company's SEPA technology with its hair regrowth product, Rogaine Topical Solution.
 MacroChem Corporation develops and licenses transdermal drug delivery compounds and systems. The company is headquartered in Lexington.
 -0- 1/25/93
 /CONTACT: Alvin J. Karloff of MacroChem Corporation, 617-862-4003/
 (MCHM UPJ)


CO: MacroChem Corporation; The Upjohn Company ST: Massachusetts, Michigan IN: MTC CHM SU: LIC

SB -- DE006 -- 8304 01/25/93 09:16 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 25, 1993
Words:319
Previous Article:CHESAPEAKE REPORTS FOURTH QUARTER EARNINGS
Next Article:GERBER REPORTS THIRD QUARTER EARNINGS OF $0.36 PER SHARE
Topics:


Related Articles
MACROCHEM ANNOUNCES UPJOHN COMMENCES PHASE III CLINICAL STUDIES AND AGREEMENT TO RAISE ADDITIONAL CAPITAL
MACROCHEM COMPLETES PRIVATE PLACEMENT
MacroChem Receives FDA Clearance of IND for Clinical Studies of Its SEPA/Testosterone Transdermal Gel
MacroChem Receives FDA Clearance of IND for Clinical Studies of Its SEPA/Testosterone Transdermal Gel
MacroChem Accelerates Development of Its Topical Gel For Erectile Dysfunction Treatment Based On Promising Results of The Ongoing Phase I/II Clinical...
U.S. Patent Office Issues 'Allowance' of all Claims in TOPIGLAN Patent Application.
Macrochem Awarded U.S. Patent on Topiglan(TM) and Announces Filing of Foreign Patents on its Antifungal Compositions.
MacroChem Announces Veterinary Pharmaceutical Development Program for Through-the-Skin Animal Drugs.
MacroChem Announces Pfizer Will Evaluate Feasibility of Improving Skin Penetration of Drugs Using MacroChem's Topical Absorption Enhancer.
John L. Zabriskie, Former Pharmacia & Upjohn CEO and Merck EVP, Elected to MacroChem Board of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters